course_id,course_code,docebo_code,course_name_input,course_name,test_id,test_name,type,question_title,answer_title,is_correct,score_if_correct,status,message,updated
4074,ILT-0000-18057,ILT-0000-18057,RCT: INSURANCE UNIVERSITY,RCT: INSURANCE UNIVERSITY,g9971,RCT: INSURANCE UNIVERSITY- g9971,choice,I acknowledge that I have read and understand this CBL,TRUE,True,100,SUCCESS: 200,"New Test with ID 15 has been created. New Question with ID 166 has been created (Test ID 15). New Answer with ID 555 has been created (Test ID 15, Question ID 166).",True
4074,ILT-0000-18057,ILT-0000-18057,RCT: INSURANCE UNIVERSITY,RCT: INSURANCE UNIVERSITY,g9971,RCT: INSURANCE UNIVERSITY- g9971,choice,I acknowledge that I have read and understand this CBL,FALSE,False,0,SUCCESS: 200,"New Answer with ID 556 has been created (Test ID 15, Question ID 166).",True
4057,ILT-0000-18039,ILT-0000-18039,RCT: CONFIDENT COLLECTOR UNIVERSITY,RCT: CONFIDENT COLLECTOR UNIVERSITY,g9970,RCT: CONFIDENT COLLECTOR UNIVERSITY- g9970,choice,I acknowledge that I have read and understand this CBL,TRUE,True,100,SUCCESS: 200,"New Test with ID 16 has been created. New Question with ID 167 has been created (Test ID 16). New Answer with ID 557 has been created (Test ID 16, Question ID 167).",True
4057,ILT-0000-18039,ILT-0000-18039,RCT: CONFIDENT COLLECTOR UNIVERSITY,RCT: CONFIDENT COLLECTOR UNIVERSITY,g9970,RCT: CONFIDENT COLLECTOR UNIVERSITY- g9970,choice,I acknowledge that I have read and understand this CBL,FALSE,False,0,SUCCESS: 200,"New Answer with ID 558 has been created (Test ID 16, Question ID 167).",True
8942,Elearning-0000-224,Elearning-0000-224,RCT: ACCOUNT RESOLUTION UNIVERSITY CBL,RCT: ACCOUNT RESOLUTION UNIVERSITY CBL,g9969,RCT: ACCOUNT RESOLUTION UNIVERSITY CBL- g9969,choice,I acknowledge that I have read and completely understand this CBL.,TRUE,True,100,SUCCESS: 200,"New Test with ID 17 has been created. New Question with ID 168 has been created (Test ID 17). New Answer with ID 559 has been created (Test ID 17, Question ID 168).",True
8942,Elearning-0000-224,Elearning-0000-224,RCT: ACCOUNT RESOLUTION UNIVERSITY CBL,RCT: ACCOUNT RESOLUTION UNIVERSITY CBL,g9969,RCT: ACCOUNT RESOLUTION UNIVERSITY CBL- g9969,choice,I acknowledge that I have read and completely understand this CBL.,FALSE,False,0,SUCCESS: 200,"New Answer with ID 560 has been created (Test ID 17, Question ID 168).",True
9085,Elearning-0000-354,Elearning-0000-354,NSH 1251 AMENDMENT 2,NSH 1251 AMENDMENT 2,g9967,NSH 1251 AMENDMENT 2- g9967,choice,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",TRUE,True,100,SUCCESS: 200,"New Test with ID 18 has been created. New Question with ID 169 has been created (Test ID 18). New Answer with ID 561 has been created (Test ID 18, Question ID 169).",True
9085,Elearning-0000-354,Elearning-0000-354,NSH 1251 AMENDMENT 2,NSH 1251 AMENDMENT 2,g9967,NSH 1251 AMENDMENT 2- g9967,choice,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",FALSE,False,0,SUCCESS: 200,"New Answer with ID 562 has been created (Test ID 18, Question ID 169).",True
9060,Elearning-0000-331,Elearning-0000-331,NSH 1170 AMENDMENT 7,NSH 1170 AMENDMENT 7,g9966,NSH 1170 AMENDMENT 7- g9966,choice,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",TRUE,True,100,SUCCESS: 200,"New Test with ID 19 has been created. New Question with ID 170 has been created (Test ID 19). New Answer with ID 563 has been created (Test ID 19, Question ID 170).",True
9060,Elearning-0000-331,Elearning-0000-331,NSH 1170 AMENDMENT 7,NSH 1170 AMENDMENT 7,g9966,NSH 1170 AMENDMENT 7- g9966,choice,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",FALSE,False,0,SUCCESS: 200,"New Answer with ID 564 has been created (Test ID 19, Question ID 170).",True
289,SCORM-0000-99,SCORM-0000-99,PREVENTION OF INFORMATION BLOCKING,PREVENTION OF INFORMATION BLOCKING,g9965,PREVENTION OF INFORMATION BLOCKING- g9965,choice,"I acknowledge that I have read and understand the ""Prevention of Information Blocking"" CBL in its entirety.",TRUE,True,100,SUCCESS: 200,"New Test with ID 20 has been created. New Question with ID 171 has been created (Test ID 20). New Answer with ID 565 has been created (Test ID 20, Question ID 171).",True
289,SCORM-0000-99,SCORM-0000-99,PREVENTION OF INFORMATION BLOCKING,PREVENTION OF INFORMATION BLOCKING,g9965,PREVENTION OF INFORMATION BLOCKING- g9965,choice,"I acknowledge that I have read and understand the ""Prevention of Information Blocking"" CBL in its entirety.",FALSE,False,0,SUCCESS: 200,"New Answer with ID 566 has been created (Test ID 20, Question ID 171).",True
9055,Elearning-0000-327,Elearning-0000-327,NSH 1184 VERSION 4.0,NSH 1184 VERSION 4.0,g9964,NSH 1184 VERSION 4.0- g9964,choice,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",TRUE,True,100,SUCCESS: 200,"New Test with ID 21 has been created. New Question with ID 172 has been created (Test ID 21). New Answer with ID 567 has been created (Test ID 21, Question ID 172).",True
9055,Elearning-0000-327,Elearning-0000-327,NSH 1184 VERSION 4.0,NSH 1184 VERSION 4.0,g9964,NSH 1184 VERSION 4.0- g9964,choice,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",FALSE,False,0,SUCCESS: 200,"New Answer with ID 568 has been created (Test ID 21, Question ID 172).",True
9052,Elearning-0000-324,Elearning-0000-324,NSH 1216 AMENDMENT 2,NSH 1216 AMENDMENT 2,g9963,NSH 1216 AMENDMENT 2- g9963,choice,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",TRUE,True,100,SUCCESS: 200,"New Test with ID 22 has been created. New Question with ID 173 has been created (Test ID 22). New Answer with ID 569 has been created (Test ID 22, Question ID 173).",True
9052,Elearning-0000-324,Elearning-0000-324,NSH 1216 AMENDMENT 2,NSH 1216 AMENDMENT 2,g9963,NSH 1216 AMENDMENT 2- g9963,choice,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",FALSE,False,0,SUCCESS: 200,"New Answer with ID 570 has been created (Test ID 22, Question ID 173).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,"As you sit down to chart you notice a message with a threat written on it, you shouldΓÇª",Throw it in the trash can immediately,False,0,SUCCESS: 200,"New Test with ID 23 has been created. New Question with ID 174 has been created (Test ID 23). New Answer with ID 571 has been created (Test ID 23, Question ID 174).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,"As you sit down to chart you notice a message with a threat written on it, you shouldΓÇª",Pick it up and take it to your charge RN or supervisor,False,0,SUCCESS: 200,"New Answer with ID 572 has been created (Test ID 23, Question ID 174).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,"As you sit down to chart you notice a message with a threat written on it, you shouldΓÇª","Handle the message as little as possible, call security and place message in clean plastic bag",False,0,SUCCESS: 200,"New Answer with ID 573 has been created (Test ID 23, Question ID 174).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,"As you sit down to chart you notice a message with a threat written on it, you shouldΓÇª","Call charge RN, supervisor and security and sweep the area for anything that looks suspicious",False,0,SUCCESS: 200,"New Answer with ID 574 has been created (Test ID 23, Question ID 174).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,"As you sit down to chart you notice a message with a threat written on it, you shouldΓÇª",Both C and D,True,100,SUCCESS: 200,"New Answer with ID 575 has been created (Test ID 23, Question ID 174).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,The best place to find policies for any emergency is,Lucidoc,True,100,SUCCESS: 200,"New Question with ID 175 has been created (Test ID 23). New Answer with ID 576 has been created (Test ID 23, Question ID 175).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,The best place to find policies for any emergency is,Netlearning,False,0,SUCCESS: 200,"New Answer with ID 577 has been created (Test ID 23, Question ID 175).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,The best place to find policies for any emergency is,The news,False,0,SUCCESS: 200,"New Answer with ID 578 has been created (Test ID 23, Question ID 175).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,You are consulting on a woman who has preeclampsia and gestational diabetes when she begins to have difficulty speaking and facial drooping. You expect that she may be having a stroke related to high blood pressure. What would you do first?,Attempt to get her to talk to you. Maybe this is temporary,False,0,SUCCESS: 200,"New Question with ID 176 has been created (Test ID 23). New Answer with ID 579 has been created (Test ID 23, Question ID 176).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,You are consulting on a woman who has preeclampsia and gestational diabetes when she begins to have difficulty speaking and facial drooping. You expect that she may be having a stroke related to high blood pressure. What would you do first?,"Call for help immediately, a stroke needs to be treated as soon as possible",True,100,SUCCESS: 200,"New Answer with ID 580 has been created (Test ID 23, Question ID 176).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,You are consulting on a woman who has preeclampsia and gestational diabetes when she begins to have difficulty speaking and facial drooping. You expect that she may be having a stroke related to high blood pressure. What would you do first?,Get a blood sugar,False,0,SUCCESS: 200,"New Answer with ID 581 has been created (Test ID 23, Question ID 176).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,The correct steps to a successful resuscitation in order of priority areΓÇª,"Activate Emergency Response, defibrillate, chest compressions, ventilate and suction",False,0,SUCCESS: 200,"New Question with ID 177 has been created (Test ID 23). New Answer with ID 582 has been created (Test ID 23, Question ID 177).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,The correct steps to a successful resuscitation in order of priority areΓÇª,"Activate Emergency Response, chest compressions, defibrillate, ventilate, and suction",True,100,SUCCESS: 200,"New Answer with ID 583 has been created (Test ID 23, Question ID 177).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,The correct steps to a successful resuscitation in order of priority areΓÇª,"Chest compressions, defibrillate, activate emergency response, ventilate and suction",False,0,SUCCESS: 200,"New Answer with ID 584 has been created (Test ID 23, Question ID 177).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,The correct steps to a successful resuscitation in order of priority areΓÇª,"Ventilate and suction, chest compressions, activate emergency response and defibrillate",False,0,SUCCESS: 200,"New Answer with ID 585 has been created (Test ID 23, Question ID 177).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,The correct rate for chest compressions on an adult is 100-120 compressions per minute,TRUE,True,100,SUCCESS: 200,"New Question with ID 178 has been created (Test ID 23). New Answer with ID 586 has been created (Test ID 23, Question ID 178).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,The correct rate for chest compressions on an adult is 100-120 compressions per minute,FALSE,False,0,SUCCESS: 200,"New Answer with ID 587 has been created (Test ID 23, Question ID 178).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,What is a special consideration when performing CPR on a pregnant woman?,Call 911 faster,False,0,SUCCESS: 200,"New Question with ID 179 has been created (Test ID 23). New Answer with ID 588 has been created (Test ID 23, Question ID 179).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,What is a special consideration when performing CPR on a pregnant woman?,Displace the gravid uterus to the left with a pillow or clothing item to help facilitate blood flow to the baby,True,100,SUCCESS: 200,"New Answer with ID 589 has been created (Test ID 23, Question ID 179).",True
9403,Elearning-0000-643,Elearning-0000-643,EMERGENCIES IN DNE,EMERGENCIES IN DNE,g9958,EMERGENCIES IN DNE- g9958,choice,What is a special consideration when performing CPR on a pregnant woman?,Consider they are more tolerant to compressions because of increased blood flow,False,0,SUCCESS: 200,"New Answer with ID 590 has been created (Test ID 23, Question ID 179).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,What is a reason for delayed Postpartum Hemorrhage (PPH)?,A. Infection,False,0,SUCCESS: 200,"New Test with ID 24 has been created. New Question with ID 180 has been created (Test ID 24). New Answer with ID 591 has been created (Test ID 24, Question ID 180).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,What is a reason for delayed Postpartum Hemorrhage (PPH)?,B. Subinvolution of uterus,False,0,SUCCESS: 200,"New Answer with ID 592 has been created (Test ID 24, Question ID 180).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,What is a reason for delayed Postpartum Hemorrhage (PPH)?,C. Retained products of conception,False,0,SUCCESS: 200,"New Answer with ID 593 has been created (Test ID 24, Question ID 180).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,What is a reason for delayed Postpartum Hemorrhage (PPH)?,D. All of the above,True,100,SUCCESS: 200,"New Answer with ID 594 has been created (Test ID 24, Question ID 180).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,What medications are used for Postpartum Hemorrhage (PPH)?,A. Tranexamic acid,False,0,SUCCESS: 200,"New Question with ID 181 has been created (Test ID 24). New Answer with ID 595 has been created (Test ID 24, Question ID 181).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,What medications are used for Postpartum Hemorrhage (PPH)?,B. Oxytocin,False,0,SUCCESS: 200,"New Answer with ID 596 has been created (Test ID 24, Question ID 181).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,What medications are used for Postpartum Hemorrhage (PPH)?,C. Hemabate,False,0,SUCCESS: 200,"New Answer with ID 597 has been created (Test ID 24, Question ID 181).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,What medications are used for Postpartum Hemorrhage (PPH)?,D. Cytotec,False,0,SUCCESS: 200,"New Answer with ID 598 has been created (Test ID 24, Question ID 181).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,What medications are used for Postpartum Hemorrhage (PPH)?,E. Methergine,False,0,SUCCESS: 200,"New Answer with ID 599 has been created (Test ID 24, Question ID 181).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,What medications are used for Postpartum Hemorrhage (PPH)?,F. All of the above,True,100,SUCCESS: 200,"New Answer with ID 600 has been created (Test ID 24, Question ID 181).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,There is a policy in Lucidoc addressing Postpartum Hemorrhage (PPH).,A. True,True,100,SUCCESS: 200,"New Question with ID 182 has been created (Test ID 24). New Answer with ID 601 has been created (Test ID 24, Question ID 182).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,There is a policy in Lucidoc addressing Postpartum Hemorrhage (PPH).,B. False,False,0,SUCCESS: 200,"New Answer with ID 602 has been created (Test ID 24, Question ID 182).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,"Postpartum Hemorrhage (PPH) is defined as a cumulative blood loss of greater than or equal to 1,000 mL or blood loss accompanied by signs or symptoms of hypovolemia within 24 hours after the birth process.",A. True,True,100,SUCCESS: 200,"New Question with ID 183 has been created (Test ID 24). New Answer with ID 603 has been created (Test ID 24, Question ID 183).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,"Postpartum Hemorrhage (PPH) is defined as a cumulative blood loss of greater than or equal to 1,000 mL or blood loss accompanied by signs or symptoms of hypovolemia within 24 hours after the birth process.",B. False,False,0,SUCCESS: 200,"New Answer with ID 604 has been created (Test ID 24, Question ID 183).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,Which of the following would be reasons for late recognition of OB Hemorrhage?,A. Under recognition of blood loss,False,0,SUCCESS: 200,"New Question with ID 184 has been created (Test ID 24). New Answer with ID 605 has been created (Test ID 24, Question ID 184).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,Which of the following would be reasons for late recognition of OB Hemorrhage?,B. Lack of attention to vital signs indicating hypovolemia,False,0,SUCCESS: 200,"New Answer with ID 606 has been created (Test ID 24, Question ID 184).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,Which of the following would be reasons for late recognition of OB Hemorrhage?,C. Failure to act decisively/failure to restore blood volume,False,0,SUCCESS: 200,"New Answer with ID 607 has been created (Test ID 24, Question ID 184).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,Which of the following would be reasons for late recognition of OB Hemorrhage?,D. All of the above,True,100,SUCCESS: 200,"New Answer with ID 608 has been created (Test ID 24, Question ID 184).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,What increases a womenΓÇÖs risk for Postpartum Hemorrhage (PPH)?,"A. Greater than 4 pregnancies, multiple gestation, advanced maternal age, and rapid delivery",False,0,SUCCESS: 200,"New Question with ID 185 has been created (Test ID 24). New Answer with ID 609 has been created (Test ID 24, Question ID 185).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,What increases a womenΓÇÖs risk for Postpartum Hemorrhage (PPH)?,"B. Prolonged labor, preeclampsia, and history of PPH",False,0,SUCCESS: 200,"New Answer with ID 610 has been created (Test ID 24, Question ID 185).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,What increases a womenΓÇÖs risk for Postpartum Hemorrhage (PPH)?,"C. Cesarean section, operative vaginal delivery, retained products of conception, undiagnosed placenta accreta spectrum, and placenta previa",False,0,SUCCESS: 200,"New Answer with ID 611 has been created (Test ID 24, Question ID 185).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,What increases a womenΓÇÖs risk for Postpartum Hemorrhage (PPH)?,D. A and C,False,0,SUCCESS: 200,"New Answer with ID 612 has been created (Test ID 24, Question ID 185).",True
8109,Elearning-0000-1008,Elearning-0000-1008,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION,g9957,SURGICAL SERVICES: FY2020 OBSTETRICAL HEMORRHAGE EDUCATION- g9957,choice,What increases a womenΓÇÖs risk for Postpartum Hemorrhage (PPH)?,E. All of the above,True,100,SUCCESS: 200,"New Answer with ID 613 has been created (Test ID 24, Question ID 185).",True
8359,Elearning-0000-1233,Elearning-0000-1233,COVID-19 GUIDELINES FOR WOMEN'S SERVICES,COVID-19 GUIDELINES FOR WOMEN'S SERVICES,g9951,COVID-19 GUIDELINES FOR WOMEN'S SERVICES- g9951,choice,"For questions about these statements, contact your manager.<br><br>  I have reviewed the ""COVID-19 Guidelines for Women's Services"" CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",TRUE,True,100,SUCCESS: 200,"New Test with ID 25 has been created. New Question with ID 186 has been created (Test ID 25). New Answer with ID 614 has been created (Test ID 25, Question ID 186).",True
8359,Elearning-0000-1233,Elearning-0000-1233,COVID-19 GUIDELINES FOR WOMEN'S SERVICES,COVID-19 GUIDELINES FOR WOMEN'S SERVICES,g9951,COVID-19 GUIDELINES FOR WOMEN'S SERVICES- g9951,choice,"For questions about these statements, contact your manager.<br><br>  I have reviewed the ""COVID-19 Guidelines for Women's Services"" CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",FALSE,False,0,SUCCESS: 200,"New Answer with ID 615 has been created (Test ID 25, Question ID 186).",True
258,SCORM-0000-68,SCORM-0000-68,NETWORK SECURITY POLICY,NETWORK SECURITY POLICY,g9947,NETWORK SECURITY POLICY- g9947,choice,"I acknowledge that I have read and understand the ""Network Security Policy"" in its entirety.",TRUE,True,100,SUCCESS: 200,"New Test with ID 26 has been created. New Question with ID 187 has been created (Test ID 26). New Answer with ID 616 has been created (Test ID 26, Question ID 187).",True
258,SCORM-0000-68,SCORM-0000-68,NETWORK SECURITY POLICY,NETWORK SECURITY POLICY,g9947,NETWORK SECURITY POLICY- g9947,choice,"I acknowledge that I have read and understand the ""Network Security Policy"" in its entirety.",FALSE,False,0,SUCCESS: 200,"New Answer with ID 617 has been created (Test ID 26, Question ID 187).",True
253,SCORM-0000-63,SCORM-0000-63,LAPTOP COMPUTER AND PORTABLE STORAGE POLICY,LAPTOP COMPUTER AND PORTABLE STORAGE POLICY,g9946,LAPTOP COMPUTER AND PORTABLE STORAGE POLICY- g9946,choice,"I acknowledge that I have read and understand the ""Laptop Computer and Portable Storage Policy"" in its entirety.",TRUE,True,100,SUCCESS: 200,"New Test with ID 27 has been created. New Question with ID 188 has been created (Test ID 27). New Answer with ID 618 has been created (Test ID 27, Question ID 188).",True
253,SCORM-0000-63,SCORM-0000-63,LAPTOP COMPUTER AND PORTABLE STORAGE POLICY,LAPTOP COMPUTER AND PORTABLE STORAGE POLICY,g9946,LAPTOP COMPUTER AND PORTABLE STORAGE POLICY- g9946,choice,"I acknowledge that I have read and understand the ""Laptop Computer and Portable Storage Policy"" in its entirety.",FALSE,False,0,SUCCESS: 200,"New Answer with ID 619 has been created (Test ID 27, Question ID 188).",True
245,SCORM-0000-55,SCORM-0000-55,INTERNET SECURITY ACCESS AND EXTERNAL EMAIL POLICY,INTERNET SECURITY ACCESS AND EXTERNAL EMAIL POLICY,g9945,INTERNET SECURITY ACCESS AND EXTERNAL EMAIL POLICY- g9945,choice,"I acknowledge that I have read and understand the ""Internet Security Access and External Email Policy"" in its entirety.",TRUE,True,100,SUCCESS: 200,"New Test with ID 28 has been created. New Question with ID 189 has been created (Test ID 28). New Answer with ID 620 has been created (Test ID 28, Question ID 189).",True
245,SCORM-0000-55,SCORM-0000-55,INTERNET SECURITY ACCESS AND EXTERNAL EMAIL POLICY,INTERNET SECURITY ACCESS AND EXTERNAL EMAIL POLICY,g9945,INTERNET SECURITY ACCESS AND EXTERNAL EMAIL POLICY- g9945,choice,"I acknowledge that I have read and understand the ""Internet Security Access and External Email Policy"" in its entirety.",FALSE,False,0,SUCCESS: 200,"New Answer with ID 621 has been created (Test ID 28, Question ID 189).",True
99,SCORM-0000-181,SCORM-0000-181,TEMPORARY TELECOMMUTING GUIDELINES,TEMPORARY TELECOMMUTING GUIDELINES,g9943,TEMPORARY TELECOMMUTING GUIDELINES- g9943,choice,"I acknowledge that I have read and understand the ""Temporary Telecommuting Guidelines"" in its entirety.",TRUE,True,100,SUCCESS: 200,"New Test with ID 29 has been created. New Question with ID 190 has been created (Test ID 29). New Answer with ID 622 has been created (Test ID 29, Question ID 190).",True
99,SCORM-0000-181,SCORM-0000-181,TEMPORARY TELECOMMUTING GUIDELINES,TEMPORARY TELECOMMUTING GUIDELINES,g9943,TEMPORARY TELECOMMUTING GUIDELINES- g9943,choice,"I acknowledge that I have read and understand the ""Temporary Telecommuting Guidelines"" in its entirety.",FALSE,False,0,SUCCESS: 200,"New Answer with ID 623 has been created (Test ID 29, Question ID 190).",True
9378,Elearning-0000-620,Elearning-0000-620,FCC RESIDENCY NAS FY2020,FCC RESIDENCY NAS FY2020,g9904,FCC RESIDENCY NAS FY2020- g9904,choice,"Drug withdrawal is a process, with symptoms that are expected to be temporary. It is NOT a birth defect.",TRUE,True,100,SUCCESS: 200,"New Test with ID 30 has been created. New Question with ID 191 has been created (Test ID 30). New Answer with ID 624 has been created (Test ID 30, Question ID 191).",True
9378,Elearning-0000-620,Elearning-0000-620,FCC RESIDENCY NAS FY2020,FCC RESIDENCY NAS FY2020,g9904,FCC RESIDENCY NAS FY2020- g9904,choice,"Drug withdrawal is a process, with symptoms that are expected to be temporary. It is NOT a birth defect.",FALSE,False,0,SUCCESS: 200,"New Answer with ID 625 has been created (Test ID 30, Question ID 191).",True
9378,Elearning-0000-620,Elearning-0000-620,FCC RESIDENCY NAS FY2020,FCC RESIDENCY NAS FY2020,g9904,FCC RESIDENCY NAS FY2020- g9904,choice,Clinical features of NAS neurological excitability include which of the following:,Tremors,False,0,SUCCESS: 200,"New Question with ID 192 has been created (Test ID 30). New Answer with ID 626 has been created (Test ID 30, Question ID 192).",True
9378,Elearning-0000-620,Elearning-0000-620,FCC RESIDENCY NAS FY2020,FCC RESIDENCY NAS FY2020,g9904,FCC RESIDENCY NAS FY2020- g9904,choice,Clinical features of NAS neurological excitability include which of the following:,Irritability,False,0,SUCCESS: 200,"New Answer with ID 627 has been created (Test ID 30, Question ID 192).",True
9378,Elearning-0000-620,Elearning-0000-620,FCC RESIDENCY NAS FY2020,FCC RESIDENCY NAS FY2020,g9904,FCC RESIDENCY NAS FY2020- g9904,choice,Clinical features of NAS neurological excitability include which of the following:,Frequent yawning,False,0,SUCCESS: 200,"New Answer with ID 628 has been created (Test ID 30, Question ID 192).",True
9378,Elearning-0000-620,Elearning-0000-620,FCC RESIDENCY NAS FY2020,FCC RESIDENCY NAS FY2020,g9904,FCC RESIDENCY NAS FY2020- g9904,choice,Clinical features of NAS neurological excitability include which of the following:,All of the above,True,100,SUCCESS: 200,"New Answer with ID 629 has been created (Test ID 30, Question ID 192).",True
9378,Elearning-0000-620,Elearning-0000-620,FCC RESIDENCY NAS FY2020,FCC RESIDENCY NAS FY2020,g9904,FCC RESIDENCY NAS FY2020- g9904,choice,Which of the following is the gold standard test for drug screening in the neonate?,Urine collected soon after birth,False,0,SUCCESS: 200,"New Question with ID 193 has been created (Test ID 30). New Answer with ID 630 has been created (Test ID 30, Question ID 193).",True
9378,Elearning-0000-620,Elearning-0000-620,FCC RESIDENCY NAS FY2020,FCC RESIDENCY NAS FY2020,g9904,FCC RESIDENCY NAS FY2020- g9904,choice,Which of the following is the gold standard test for drug screening in the neonate?,Meconium,True,100,SUCCESS: 200,"New Answer with ID 631 has been created (Test ID 30, Question ID 193).",True
9378,Elearning-0000-620,Elearning-0000-620,FCC RESIDENCY NAS FY2020,FCC RESIDENCY NAS FY2020,g9904,FCC RESIDENCY NAS FY2020- g9904,choice,Which of the following is the gold standard test for drug screening in the neonate?,Umbilical cord,False,0,SUCCESS: 200,"New Answer with ID 632 has been created (Test ID 30, Question ID 193).",True
9378,Elearning-0000-620,Elearning-0000-620,FCC RESIDENCY NAS FY2020,FCC RESIDENCY NAS FY2020,g9904,FCC RESIDENCY NAS FY2020- g9904,choice,Which of the following is the gold standard test for drug screening in the neonate?,All of the above,False,0,SUCCESS: 200,"New Answer with ID 633 has been created (Test ID 30, Question ID 193).",True
9378,Elearning-0000-620,Elearning-0000-620,FCC RESIDENCY NAS FY2020,FCC RESIDENCY NAS FY2020,g9904,FCC RESIDENCY NAS FY2020- g9904,choice,You discover that a mother used Percocet 5mg daily throughout her pregnancy for chronic back pain. What is the appropriate nursing action?,Nothing since it is a prescribed medication.,False,0,SUCCESS: 200,"New Question with ID 194 has been created (Test ID 30). New Answer with ID 634 has been created (Test ID 30, Question ID 194).",True
9378,Elearning-0000-620,Elearning-0000-620,FCC RESIDENCY NAS FY2020,FCC RESIDENCY NAS FY2020,g9904,FCC RESIDENCY NAS FY2020- g9904,choice,You discover that a mother used Percocet 5mg daily throughout her pregnancy for chronic back pain. What is the appropriate nursing action?,Notify pediatrician and begin NAS scoring every 4 hours.,True,100,SUCCESS: 200,"New Answer with ID 635 has been created (Test ID 30, Question ID 194).",True
9378,Elearning-0000-620,Elearning-0000-620,FCC RESIDENCY NAS FY2020,FCC RESIDENCY NAS FY2020,g9904,FCC RESIDENCY NAS FY2020- g9904,choice,You discover that a mother used Percocet 5mg daily throughout her pregnancy for chronic back pain. What is the appropriate nursing action?,Instruct the mother to not breastfeed.,False,0,SUCCESS: 200,"New Answer with ID 636 has been created (Test ID 30, Question ID 194).",True
9378,Elearning-0000-620,Elearning-0000-620,FCC RESIDENCY NAS FY2020,FCC RESIDENCY NAS FY2020,g9904,FCC RESIDENCY NAS FY2020- g9904,choice,You discover that a mother used Percocet 5mg daily throughout her pregnancy for chronic back pain. What is the appropriate nursing action?,All of the above,False,0,SUCCESS: 200,"New Answer with ID 637 has been created (Test ID 30, Question ID 194).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,Which of the following BP values is considered hypertension?,145/85,False,0,SUCCESS: 200,"New Test with ID 31 has been created. New Question with ID 195 has been created (Test ID 31). New Answer with ID 638 has been created (Test ID 31, Question ID 195).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,Which of the following BP values is considered hypertension?,136/92,False,0,SUCCESS: 200,"New Answer with ID 639 has been created (Test ID 31, Question ID 195).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,Which of the following BP values is considered hypertension?,166/95,False,0,SUCCESS: 200,"New Answer with ID 640 has been created (Test ID 31, Question ID 195).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,Which of the following BP values is considered hypertension?,All of the above,True,100,SUCCESS: 200,"New Answer with ID 641 has been created (Test ID 31, Question ID 195).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,According to NEWT when should the provider be notified for new onset elevated BP (not hypertensive emergency)?,One occasion of elevated blood pressure,False,0,SUCCESS: 200,"New Question with ID 196 has been created (Test ID 31). New Answer with ID 642 has been created (Test ID 31, Question ID 196).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,According to NEWT when should the provider be notified for new onset elevated BP (not hypertensive emergency)?,2 consecutive occasions of elevated blood pressure,False,0,SUCCESS: 200,"New Answer with ID 643 has been created (Test ID 31, Question ID 196).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,According to NEWT when should the provider be notified for new onset elevated BP (not hypertensive emergency)?,2 separate occasions of elevated blood pressure within 4 hours,True,100,SUCCESS: 200,"New Answer with ID 644 has been created (Test ID 31, Question ID 196).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,According to NEWT when should the provider be notified for new onset elevated BP (not hypertensive emergency)?,A minimum of 3 elevated blood pressure occasions and evidence of organ involvement,False,0,SUCCESS: 200,"New Answer with ID 645 has been created (Test ID 31, Question ID 196).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,What does HELLP stand for?,"Hemolysis, Elevated Liver Enzymes, Low Platelets",True,100,SUCCESS: 200,"New Question with ID 197 has been created (Test ID 31). New Answer with ID 646 has been created (Test ID 31, Question ID 197).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,What does HELLP stand for?,"Hemoglobin, Eosinophils, Lung sounds, Liver enzymes, Proteinuria",False,0,SUCCESS: 200,"New Answer with ID 647 has been created (Test ID 31, Question ID 197).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,What does HELLP stand for?,"Hematocrit, Elevated BP, Low Liver Enzymes, Platelets",False,0,SUCCESS: 200,"New Answer with ID 648 has been created (Test ID 31, Question ID 197).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,What does HELLP stand for?,"Headache, Elevated BP, Liver Enzymes, Low Platelets",False,0,SUCCESS: 200,"New Answer with ID 649 has been created (Test ID 31, Question ID 197).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,How is Acute Hypertensive Emergency defined?,BP greater than or equal to 185/110,False,0,SUCCESS: 200,"New Question with ID 198 has been created (Test ID 31). New Answer with ID 650 has been created (Test ID 31, Question ID 198).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,How is Acute Hypertensive Emergency defined?,Systolic BP greater than or equal to 140 or Diastolic BP greater than or equal to 90,False,0,SUCCESS: 200,"New Answer with ID 651 has been created (Test ID 31, Question ID 198).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,How is Acute Hypertensive Emergency defined?,Systolic BP greater than or equal to 160 or Diastolic BP greater than or equal to 110,False,0,SUCCESS: 200,"New Answer with ID 652 has been created (Test ID 31, Question ID 198).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,How is Acute Hypertensive Emergency defined?,"Systolic BP greater than or equal to 160 or Diastolic BP greater than or equal to 110, sustained for 15 minutes",True,100,SUCCESS: 200,"New Answer with ID 653 has been created (Test ID 31, Question ID 198).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,What is the best way to predict that your patient will develop eclampsia?,There is no way to predict who will develop eclampsia,True,100,SUCCESS: 200,"New Question with ID 199 has been created (Test ID 31). New Answer with ID 654 has been created (Test ID 31, Question ID 199).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,What is the best way to predict that your patient will develop eclampsia?,Patients presenting with headache and visual disturbances,False,0,SUCCESS: 200,"New Answer with ID 655 has been created (Test ID 31, Question ID 199).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,What is the best way to predict that your patient will develop eclampsia?,Patients whose BP is greater than 160/110,False,0,SUCCESS: 200,"New Answer with ID 656 has been created (Test ID 31, Question ID 199).",True
9381,Elearning-0000-623,Elearning-0000-623,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020,g9900,FCC RESIDENCY HYPERTENSION IN PREGNANCY FY2020- g9900,choice,What is the best way to predict that your patient will develop eclampsia?,Patient whose BP is greater than 200/100,False,0,SUCCESS: 200,"New Answer with ID 657 has been created (Test ID 31, Question ID 199).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,What assessments are performed if the newborn is exhibiting signs of respiratory distress?,"Respiratory rate, pulse oximetry, breath sounds, work of breathing, and color.",True,100,SUCCESS: 200,"New Test with ID 32 has been created. New Question with ID 200 has been created (Test ID 32). New Answer with ID 658 has been created (Test ID 32, Question ID 200).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,What assessments are performed if the newborn is exhibiting signs of respiratory distress?,"Heart rate, blood sugar, temperature, and capillary refill.",False,0,SUCCESS: 200,"New Answer with ID 659 has been created (Test ID 32, Question ID 200).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,What assessments are performed if the newborn is exhibiting signs of respiratory distress?,"Weight, feeding status, amount of time in between feedings, and regurgitations of feedings.",False,0,SUCCESS: 200,"New Answer with ID 660 has been created (Test ID 32, Question ID 200).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,What assessments are performed if the newborn is exhibiting signs of respiratory distress?,"Temperature, sweating, maternal labs, method of delivery.",False,0,SUCCESS: 200,"New Answer with ID 661 has been created (Test ID 32, Question ID 200).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,Pallor is more concerning than cyanosis in an infant.,TRUE,True,100,SUCCESS: 200,"New Question with ID 201 has been created (Test ID 32). New Answer with ID 662 has been created (Test ID 32, Question ID 201).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,Pallor is more concerning than cyanosis in an infant.,FALSE,False,0,SUCCESS: 200,"New Answer with ID 663 has been created (Test ID 32, Question ID 201).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,How do we call a code for a baby that is in distress?,Dial 8911.,False,0,SUCCESS: 200,"New Question with ID 202 has been created (Test ID 32). New Answer with ID 664 has been created (Test ID 32, Question ID 202).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,How do we call a code for a baby that is in distress?,Call 911.,False,0,SUCCESS: 200,"New Answer with ID 665 has been created (Test ID 32, Question ID 202).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,How do we call a code for a baby that is in distress?,Obtain help from your supervisor only.,False,0,SUCCESS: 200,"New Answer with ID 666 has been created (Test ID 32, Question ID 202).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,How do we call a code for a baby that is in distress?,Call the Resus team by the white phone or dial 7323.,True,100,SUCCESS: 200,"New Answer with ID 667 has been created (Test ID 32, Question ID 202).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,One way to determine if the baby is seizing vs. jitteriness is to place a hand on the affected area. If the movement stops it does not indicate a seizure.,TRUE,True,100,SUCCESS: 200,"New Question with ID 203 has been created (Test ID 32). New Answer with ID 668 has been created (Test ID 32, Question ID 203).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,One way to determine if the baby is seizing vs. jitteriness is to place a hand on the affected area. If the movement stops it does not indicate a seizure.,FALSE,False,0,SUCCESS: 200,"New Answer with ID 669 has been created (Test ID 32, Question ID 203).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,"If a baby is dropped, or their head is hit on an object, it needs to be reported immediately for further evaluation to ensure no harm has come to the baby.",TRUE,True,100,SUCCESS: 200,"New Question with ID 204 has been created (Test ID 32). New Answer with ID 670 has been created (Test ID 32, Question ID 204).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,"If a baby is dropped, or their head is hit on an object, it needs to be reported immediately for further evaluation to ensure no harm has come to the baby.",FALSE,False,0,SUCCESS: 200,"New Answer with ID 671 has been created (Test ID 32, Question ID 204).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,A mother falls asleep with her baby and accidently drops the baby onto the floor. She is too embarrassed to tell and does not inform the staff until many hours later. The newborn is transferred to special care nursery for observation and further testing. How will you discuss this matter with the parents?,"Educate the parents on the process that is going to take place with the baby. The location of the baby, and the contact information on how to reach the area that the baby is located.",True,100,SUCCESS: 200,"New Question with ID 205 has been created (Test ID 32). New Answer with ID 672 has been created (Test ID 32, Question ID 205).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,A mother falls asleep with her baby and accidently drops the baby onto the floor. She is too embarrassed to tell and does not inform the staff until many hours later. The newborn is transferred to special care nursery for observation and further testing. How will you discuss this matter with the parents?,Place blame on the parents for not telling staff earlier.,False,0,SUCCESS: 200,"New Answer with ID 673 has been created (Test ID 32, Question ID 205).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,A mother falls asleep with her baby and accidently drops the baby onto the floor. She is too embarrassed to tell and does not inform the staff until many hours later. The newborn is transferred to special care nursery for observation and further testing. How will you discuss this matter with the parents?,Tell the parents that only Special Care nursery staff has the information they need and will be in touch with them when they figure out what is wrong with the baby.,False,0,SUCCESS: 200,"New Answer with ID 674 has been created (Test ID 32, Question ID 205).",True
9376,Elearning-0000-619,Elearning-0000-619,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,FCC RESIDENCY NEWBORN EMERGENCIES FY2020,g9899,FCC RESIDENCY NEWBORN EMERGENCIES FY2020- g9899,choice,A mother falls asleep with her baby and accidently drops the baby onto the floor. She is too embarrassed to tell and does not inform the staff until many hours later. The newborn is transferred to special care nursery for observation and further testing. How will you discuss this matter with the parents?,Transfer the baby and do not discuss anything with the parents. ItΓÇÖs not your place.,False,0,SUCCESS: 200,"New Answer with ID 675 has been created (Test ID 32, Question ID 205).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,A patient who delivered a baby a month ago is no longer considered an obstetric patient?,TRUE,False,0,SUCCESS: 200,"New Test with ID 33 has been created. New Question with ID 206 has been created (Test ID 33). New Answer with ID 676 has been created (Test ID 33, Question ID 206).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,A patient who delivered a baby a month ago is no longer considered an obstetric patient?,FALSE,True,100,SUCCESS: 200,"New Answer with ID 677 has been created (Test ID 33, Question ID 206).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,A 32-year-old female reports vaginal bleeding in triage.  What should you ask her?,A. Could you be pregnant?,False,0,SUCCESS: 200,"New Question with ID 207 has been created (Test ID 33). New Answer with ID 678 has been created (Test ID 33, Question ID 207).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,A 32-year-old female reports vaginal bleeding in triage.  What should you ask her?,B. Have you been pregnant within the last 6 weeks?,False,0,SUCCESS: 200,"New Answer with ID 679 has been created (Test ID 33, Question ID 207).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,A 32-year-old female reports vaginal bleeding in triage.  What should you ask her?,C. Both A & B,True,100,SUCCESS: 200,"New Answer with ID 680 has been created (Test ID 33, Question ID 207).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,A 32-year-old female reports vaginal bleeding in triage.  What should you ask her?,D. None of the above,False,0,SUCCESS: 200,"New Answer with ID 681 has been created (Test ID 33, Question ID 207).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,A patient who is two weeks post-partum presents with heavy vaginal bleeding.  What does the initial treatment for this patient include?,Notify physician,False,0,SUCCESS: 200,"New Question with ID 208 has been created (Test ID 33). New Answer with ID 682 has been created (Test ID 33, Question ID 208).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,A patient who is two weeks post-partum presents with heavy vaginal bleeding.  What does the initial treatment for this patient include?,Obtain IV access and rainbow draw labs,False,0,SUCCESS: 200,"New Answer with ID 683 has been created (Test ID 33, Question ID 208).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,A patient who is two weeks post-partum presents with heavy vaginal bleeding.  What does the initial treatment for this patient include?,Anticipate transfer to OR,False,0,SUCCESS: 200,"New Answer with ID 684 has been created (Test ID 33, Question ID 208).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,A patient who is two weeks post-partum presents with heavy vaginal bleeding.  What does the initial treatment for this patient include?,All of the above,True,100,SUCCESS: 200,"New Answer with ID 685 has been created (Test ID 33, Question ID 208).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,A patient who is 4 weeks post-partum presents to triage with a headache.  Initial blood pressure is 164/92.  A re-check of her BP later is 168/98.  What is your FIRST action?,Take her to Labor & Delivery,False,0,SUCCESS: 200,"New Question with ID 209 has been created (Test ID 33). New Answer with ID 686 has been created (Test ID 33, Question ID 209).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,A patient who is 4 weeks post-partum presents to triage with a headache.  Initial blood pressure is 164/92.  A re-check of her BP later is 168/98.  What is your FIRST action?,Notify the ED physician,True,100,SUCCESS: 200,"New Answer with ID 687 has been created (Test ID 33, Question ID 209).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,A patient who is 4 weeks post-partum presents to triage with a headache.  Initial blood pressure is 164/92.  A re-check of her BP later is 168/98.  What is your FIRST action?,Give Labetalol 40mg IVP,False,0,SUCCESS: 200,"New Answer with ID 688 has been created (Test ID 33, Question ID 209).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,A patient who is 4 weeks post-partum presents to triage with a headache.  Initial blood pressure is 164/92.  A re-check of her BP later is 168/98.  What is your FIRST action?,Wait 60 minutes and re-check the blood pressure,False,0,SUCCESS: 200,"New Answer with ID 689 has been created (Test ID 33, Question ID 209).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,Which of the following is NOT a medication typically used to treat obstetrical hypertension?,SL Nitroglycerin,True,100,SUCCESS: 200,"New Question with ID 210 has been created (Test ID 33). New Answer with ID 690 has been created (Test ID 33, Question ID 210).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,Which of the following is NOT a medication typically used to treat obstetrical hypertension?,IV Labetalol,False,0,SUCCESS: 200,"New Answer with ID 691 has been created (Test ID 33, Question ID 210).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,Which of the following is NOT a medication typically used to treat obstetrical hypertension?,IV Hydralazine,False,0,SUCCESS: 200,"New Answer with ID 692 has been created (Test ID 33, Question ID 210).",True
9409,Elearning-0000-649,Elearning-0000-649,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION,g9885,ED OBSTETRICAL HEMORRHAGE AND HYPERTENSION- g9885,choice,Which of the following is NOT a medication typically used to treat obstetrical hypertension?,PO Nifedipine,False,0,SUCCESS: 200,"New Answer with ID 693 has been created (Test ID 33, Question ID 210).",True
1212,ILT-0000-4902,ILT-0000-4902,COVID-19,COVID-19,g9882,COVID-19- g9882,choice,"I acknowledge that I have read and understand the ""UPDATE ON COVID-19"" CBL in its entirety.",TRUE,True,100,SUCCESS: 200,"New Test with ID 34 has been created. New Question with ID 211 has been created (Test ID 34). New Answer with ID 694 has been created (Test ID 34, Question ID 211).",True
1212,ILT-0000-4902,ILT-0000-4902,COVID-19,COVID-19,g9882,COVID-19- g9882,choice,"I acknowledge that I have read and understand the ""UPDATE ON COVID-19"" CBL in its entirety.",FALSE,False,0,SUCCESS: 200,"New Answer with ID 695 has been created (Test ID 34, Question ID 211).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,The Global Surgical Package is a single payment for all care associate with a surgical procedure.,TRUE,True,100,SUCCESS: 200,"New Test with ID 35 has been created. New Question with ID 212 has been created (Test ID 35). New Answer with ID 696 has been created (Test ID 35, Question ID 212).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,The Global Surgical Package is a single payment for all care associate with a surgical procedure.,FALSE,False,0,SUCCESS: 200,"New Answer with ID 697 has been created (Test ID 35, Question ID 212).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Payment is based on which phase of the surgical procedure.,A) Preoperative evaluation,False,0,SUCCESS: 200,"New Question with ID 213 has been created (Test ID 35). New Answer with ID 698 has been created (Test ID 35, Question ID 213).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Payment is based on which phase of the surgical procedure.,B) Intra-operative procedure,False,0,SUCCESS: 200,"New Answer with ID 699 has been created (Test ID 35, Question ID 213).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Payment is based on which phase of the surgical procedure.,"C) Postoperative care for either 0, 10, 90 days",False,0,SUCCESS: 200,"New Answer with ID 700 has been created (Test ID 35, Question ID 213).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Payment is based on which phase of the surgical procedure.,D) All of the above,True,100,SUCCESS: 200,"New Answer with ID 701 has been created (Test ID 35, Question ID 213).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Payment is based on which phase of the surgical procedure.,E) C only,False,0,SUCCESS: 200,"New Answer with ID 702 has been created (Test ID 35, Question ID 213).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Services that are normally a ΓÇ£usual and necessaryΓÇ¥ part of the surgical procedure are considered a part of the Postoperative Care phase.,TRUE,False,0,SUCCESS: 200,"New Question with ID 214 has been created (Test ID 35). New Answer with ID 703 has been created (Test ID 35, Question ID 214).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Services that are normally a ΓÇ£usual and necessaryΓÇ¥ part of the surgical procedure are considered a part of the Postoperative Care phase.,FALSE,True,100,SUCCESS: 200,"New Answer with ID 704 has been created (Test ID 35, Question ID 214).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,The following services are included in the postoperative care:,A) Local incision care,False,0,SUCCESS: 200,"New Question with ID 215 has been created (Test ID 35). New Answer with ID 705 has been created (Test ID 35, Question ID 215).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,The following services are included in the postoperative care:,B) Decision for surgery,False,0,SUCCESS: 200,"New Answer with ID 706 has been created (Test ID 35, Question ID 215).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,The following services are included in the postoperative care:,C) Postoperative pain management,False,0,SUCCESS: 200,"New Answer with ID 707 has been created (Test ID 35, Question ID 215).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,The following services are included in the postoperative care:,D) A and B,False,0,SUCCESS: 200,"New Answer with ID 708 has been created (Test ID 35, Question ID 215).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,The following services are included in the postoperative care:,E) A and C,True,100,SUCCESS: 200,"New Answer with ID 709 has been created (Test ID 35, Question ID 215).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Which surgical indicator represents Endoscopies?,A) ΓÇ£ZZZΓÇ¥,False,0,SUCCESS: 200,"New Question with ID 216 has been created (Test ID 35). New Answer with ID 710 has been created (Test ID 35, Question ID 216).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Which surgical indicator represents Endoscopies?,B) ΓÇ£000ΓÇ¥,True,100,SUCCESS: 200,"New Answer with ID 711 has been created (Test ID 35, Question ID 216).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Which surgical indicator represents Endoscopies?,C) ΓÇ£090ΓÇ¥,False,0,SUCCESS: 200,"New Answer with ID 712 has been created (Test ID 35, Question ID 216).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Which surgical indicator represents Endoscopies?,D) ΓÇ£YYYΓÇ¥,False,0,SUCCESS: 200,"New Answer with ID 713 has been created (Test ID 35, Question ID 216).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Which surgical indicator represents Endoscopies?,E) ΓÇ£010ΓÇ¥,False,0,SUCCESS: 200,"New Answer with ID 714 has been created (Test ID 35, Question ID 216).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,"An endoscopy represents a simple procedure, wherein there is no preoperative/postoperative period and the global period is only the day of the procedure.",TRUE,True,100,SUCCESS: 200,"New Question with ID 217 has been created (Test ID 35). New Answer with ID 715 has been created (Test ID 35, Question ID 217).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,"An endoscopy represents a simple procedure, wherein there is no preoperative/postoperative period and the global period is only the day of the procedure.",FALSE,False,0,SUCCESS: 200,"New Answer with ID 716 has been created (Test ID 35, Question ID 217).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,There are 92 days in the global surgical period for major surgical procedures.,TRUE,True,100,SUCCESS: 200,"New Question with ID 218 has been created (Test ID 35). New Answer with ID 717 has been created (Test ID 35, Question ID 218).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,There are 92 days in the global surgical period for major surgical procedures.,FALSE,False,0,SUCCESS: 200,"New Answer with ID 718 has been created (Test ID 35, Question ID 218).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,The global surgical package <u>includes</u> return trips to the operating room for complications from surgery.,TRUE,False,0,SUCCESS: 200,"New Question with ID 219 has been created (Test ID 35). New Answer with ID 719 has been created (Test ID 35, Question ID 219).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,The global surgical package <u>includes</u> return trips to the operating room for complications from surgery.,FALSE,True,100,SUCCESS: 200,"New Answer with ID 720 has been created (Test ID 35, Question ID 219).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Global surgery only applies in the inpatient hospital setting.,TRUE,False,0,SUCCESS: 200,"New Question with ID 220 has been created (Test ID 35). New Answer with ID 721 has been created (Test ID 35, Question ID 220).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Global surgery only applies in the inpatient hospital setting.,FALSE,True,100,SUCCESS: 200,"New Answer with ID 722 has been created (Test ID 35, Question ID 220).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Postoperative E/M visits included in the global period are reported with:,A) 99204,False,0,SUCCESS: 200,"New Question with ID 221 has been created (Test ID 35). New Answer with ID 723 has been created (Test ID 35, Question ID 221).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Postoperative E/M visits included in the global period are reported with:,B) 99214,False,0,SUCCESS: 200,"New Answer with ID 724 has been created (Test ID 35, Question ID 221).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Postoperative E/M visits included in the global period are reported with:,C) 99244,False,0,SUCCESS: 200,"New Answer with ID 725 has been created (Test ID 35, Question ID 221).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Postoperative E/M visits included in the global period are reported with:,D) 99024,True,100,SUCCESS: 200,"New Answer with ID 726 has been created (Test ID 35, Question ID 221).",True
8128,Elearning-0000-1025,Elearning-0000-1025,REV INT - GLOBAL SURGICAL PACKAGE,REV INT - GLOBAL SURGICAL PACKAGE,g9878,REV INT - GLOBAL SURGICAL PACKAGE- g9878,choice,Postoperative E/M visits included in the global period are reported with:,E) Not reported,False,0,SUCCESS: 200,"New Answer with ID 727 has been created (Test ID 35, Question ID 221).",True
9792,Elearning-0000-997,Elearning-0000-997,SURGICAL SERVICES: STANDARD PRECAUTIONS AND ISOLATION POLICY UPDATES,SURGICAL SERVICES: STANDARD PRECAUTIONS AND ISOLATION POLICY UPDATES,g9869,SURGICAL SERVICES: STANDARD PRECAUTIONS AND ISOLATION POLICY UPDATES- g9869,choice,"For questions about these statements, contact your manager.<br><br>  I have reviewed the ""Surgical Services: Standard Precautions and Isolation Policy Updates"" CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",TRUE,True,100,SUCCESS: 200,"New Test with ID 36 has been created. New Question with ID 222 has been created (Test ID 36). New Answer with ID 728 has been created (Test ID 36, Question ID 222).",True
9792,Elearning-0000-997,Elearning-0000-997,SURGICAL SERVICES: STANDARD PRECAUTIONS AND ISOLATION POLICY UPDATES,SURGICAL SERVICES: STANDARD PRECAUTIONS AND ISOLATION POLICY UPDATES,g9869,SURGICAL SERVICES: STANDARD PRECAUTIONS AND ISOLATION POLICY UPDATES- g9869,choice,"For questions about these statements, contact your manager.<br><br>  I have reviewed the ""Surgical Services: Standard Precautions and Isolation Policy Updates"" CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",FALSE,False,0,SUCCESS: 200,"New Answer with ID 729 has been created (Test ID 36, Question ID 222).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,Select the antigens below that are the frameworks of the ABO system:,A,False,0,SUCCESS: 200,"New Test with ID 37 has been created. New Question with ID 223 has been created (Test ID 37). New Answer with ID 730 has been created (Test ID 37, Question ID 223).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,Select the antigens below that are the frameworks of the ABO system:,B,False,0,SUCCESS: 200,"New Answer with ID 731 has been created (Test ID 37, Question ID 223).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,Select the antigens below that are the frameworks of the ABO system:,O,False,0,SUCCESS: 200,"New Answer with ID 732 has been created (Test ID 37, Question ID 223).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,Select the antigens below that are the frameworks of the ABO system:,A and B only,True,100,SUCCESS: 200,"New Answer with ID 733 has been created (Test ID 37, Question ID 223).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,If someone is Rh positive this means they have a D antigen on their red blood cell.,TRUE,True,100,SUCCESS: 200,"New Question with ID 224 has been created (Test ID 37). New Answer with ID 734 has been created (Test ID 37, Question ID 224).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,If someone is Rh positive this means they have a D antigen on their red blood cell.,FALSE,False,0,SUCCESS: 200,"New Answer with ID 735 has been created (Test ID 37, Question ID 224).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,An antibody is a protein produced by the immune system in response to the presence of an antigen.,TRUE,True,100,SUCCESS: 200,"New Question with ID 225 has been created (Test ID 37). New Answer with ID 736 has been created (Test ID 37, Question ID 225).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,An antibody is a protein produced by the immune system in response to the presence of an antigen.,FALSE,False,0,SUCCESS: 200,"New Answer with ID 737 has been created (Test ID 37, Question ID 225).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,"If someoneΓÇÖs blood phenotype is A, what are their possible genotypes?",AA,False,0,SUCCESS: 200,"New Question with ID 226 has been created (Test ID 37). New Answer with ID 738 has been created (Test ID 37, Question ID 226).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,"If someoneΓÇÖs blood phenotype is A, what are their possible genotypes?",AO,False,0,SUCCESS: 200,"New Answer with ID 739 has been created (Test ID 37, Question ID 226).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,"If someoneΓÇÖs blood phenotype is A, what are their possible genotypes?",AB,False,0,SUCCESS: 200,"New Answer with ID 740 has been created (Test ID 37, Question ID 226).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,"If someoneΓÇÖs blood phenotype is A, what are their possible genotypes?",AA and AO,True,100,SUCCESS: 200,"New Answer with ID 741 has been created (Test ID 37, Question ID 226).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,Rh sensitization occurs when an Rh negative mother comes in contact with Rh positive blood.,TRUE,True,100,SUCCESS: 200,"New Question with ID 227 has been created (Test ID 37). New Answer with ID 742 has been created (Test ID 37, Question ID 227).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,Rh sensitization occurs when an Rh negative mother comes in contact with Rh positive blood.,FALSE,False,0,SUCCESS: 200,"New Answer with ID 743 has been created (Test ID 37, Question ID 227).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,Newborn consequences of maternal newborn blood incompatibility include which of the following:,Anemia,False,0,SUCCESS: 200,"New Question with ID 228 has been created (Test ID 37). New Answer with ID 744 has been created (Test ID 37, Question ID 228).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,Newborn consequences of maternal newborn blood incompatibility include which of the following:,Jaundice,False,0,SUCCESS: 200,"New Answer with ID 745 has been created (Test ID 37, Question ID 228).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,Newborn consequences of maternal newborn blood incompatibility include which of the following:,Hydrops Fetalis,False,0,SUCCESS: 200,"New Answer with ID 746 has been created (Test ID 37, Question ID 228).",True
9383,Elearning-0000-625,Elearning-0000-625,FCC RESIDENCY ABO FY2020,FCC RESIDENCY ABO FY2020,g9868,FCC RESIDENCY ABO FY2020- g9868,choice,Newborn consequences of maternal newborn blood incompatibility include which of the following:,All of the above,True,100,SUCCESS: 200,"New Answer with ID 747 has been created (Test ID 37, Question ID 228).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,Please list the location for this activity.,Atlanta,False,0,SUCCESS: 200,"New Test with ID 38 has been created. New Question with ID 229 has been created (Test ID 38). New Answer with ID 748 has been created (Test ID 38, Question ID 229).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,Please list the location for this activity.,Cherokee,False,0,SUCCESS: 200,"New Answer with ID 749 has been created (Test ID 38, Question ID 229).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,Please list the location for this activity.,Forsyth,False,0,SUCCESS: 200,"New Answer with ID 750 has been created (Test ID 38, Question ID 229).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,Please list the location for this activity.,Other,False,0,SUCCESS: 200,"New Answer with ID 751 has been created (Test ID 38, Question ID 229).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss evidenced based diagnosis and treatment strategies for COPD.  </ol>",Strongly Agree,False,0,SUCCESS: 200,"New Question with ID 230 has been created (Test ID 38). New Answer with ID 752 has been created (Test ID 38, Question ID 230).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss evidenced based diagnosis and treatment strategies for COPD.  </ol>",Agree,False,0,SUCCESS: 200,"New Answer with ID 753 has been created (Test ID 38, Question ID 230).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss evidenced based diagnosis and treatment strategies for COPD.  </ol>",No Opinion,False,0,SUCCESS: 200,"New Answer with ID 754 has been created (Test ID 38, Question ID 230).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss evidenced based diagnosis and treatment strategies for COPD.  </ol>",Disagree,False,0,SUCCESS: 200,"New Answer with ID 755 has been created (Test ID 38, Question ID 230).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss evidenced based diagnosis and treatment strategies for COPD.  </ol>",Strongly Disagree,False,0,SUCCESS: 200,"New Answer with ID 756 has been created (Test ID 38, Question ID 230).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the impact of inspiratory flow on device selection.</ol>",Strongly Agree,False,0,SUCCESS: 200,"New Question with ID 231 has been created (Test ID 38). New Answer with ID 757 has been created (Test ID 38, Question ID 231).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the impact of inspiratory flow on device selection.</ol>",Agree,False,0,SUCCESS: 200,"New Answer with ID 758 has been created (Test ID 38, Question ID 231).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the impact of inspiratory flow on device selection.</ol>",No Opinion,False,0,SUCCESS: 200,"New Answer with ID 759 has been created (Test ID 38, Question ID 231).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the impact of inspiratory flow on device selection.</ol>",Disagree,False,0,SUCCESS: 200,"New Answer with ID 760 has been created (Test ID 38, Question ID 231).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the impact of inspiratory flow on device selection.</ol>",Strongly Disagree,False,0,SUCCESS: 200,"New Answer with ID 761 has been created (Test ID 38, Question ID 231).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of GOLD guidelines to improving outcomes for patients with COPD.</ol>",Strongly Agree,False,0,SUCCESS: 200,"New Question with ID 232 has been created (Test ID 38). New Answer with ID 762 has been created (Test ID 38, Question ID 232).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of GOLD guidelines to improving outcomes for patients with COPD.</ol>",Agree,False,0,SUCCESS: 200,"New Answer with ID 763 has been created (Test ID 38, Question ID 232).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of GOLD guidelines to improving outcomes for patients with COPD.</ol>",No Opinion,False,0,SUCCESS: 200,"New Answer with ID 764 has been created (Test ID 38, Question ID 232).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of GOLD guidelines to improving outcomes for patients with COPD.</ol>",Disagree,False,0,SUCCESS: 200,"New Answer with ID 765 has been created (Test ID 38, Question ID 232).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of GOLD guidelines to improving outcomes for patients with COPD.</ol>",Strongly Disagree,False,0,SUCCESS: 200,"New Answer with ID 766 has been created (Test ID 38, Question ID 232).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to match device selection with patient capabilities and state critical steps in inhaler device education. </ol>",Strongly Agree,False,0,SUCCESS: 200,"New Question with ID 233 has been created (Test ID 38). New Answer with ID 767 has been created (Test ID 38, Question ID 233).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to match device selection with patient capabilities and state critical steps in inhaler device education. </ol>",Agree,False,0,SUCCESS: 200,"New Answer with ID 768 has been created (Test ID 38, Question ID 233).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to match device selection with patient capabilities and state critical steps in inhaler device education. </ol>",No Opinion,False,0,SUCCESS: 200,"New Answer with ID 769 has been created (Test ID 38, Question ID 233).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to match device selection with patient capabilities and state critical steps in inhaler device education. </ol>",Disagree,False,0,SUCCESS: 200,"New Answer with ID 770 has been created (Test ID 38, Question ID 233).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to match device selection with patient capabilities and state critical steps in inhaler device education. </ol>",Strongly Disagree,False,0,SUCCESS: 200,"New Answer with ID 771 has been created (Test ID 38, Question ID 233).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the impact of nicotine dependency and vaping on the pulmonary system.</ol>",Strongly Agree,False,0,SUCCESS: 200,"New Question with ID 234 has been created (Test ID 38). New Answer with ID 772 has been created (Test ID 38, Question ID 234).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the impact of nicotine dependency and vaping on the pulmonary system.</ol>",Agree,False,0,SUCCESS: 200,"New Answer with ID 773 has been created (Test ID 38, Question ID 234).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the impact of nicotine dependency and vaping on the pulmonary system.</ol>",No Opinion,False,0,SUCCESS: 200,"New Answer with ID 774 has been created (Test ID 38, Question ID 234).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the impact of nicotine dependency and vaping on the pulmonary system.</ol>",Disagree,False,0,SUCCESS: 200,"New Answer with ID 775 has been created (Test ID 38, Question ID 234).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the impact of nicotine dependency and vaping on the pulmonary system.</ol>",Strongly Disagree,False,0,SUCCESS: 200,"New Answer with ID 776 has been created (Test ID 38, Question ID 234).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify steps for engaging patients in successful management of their COPD.</ol>",Strongly Agree,False,0,SUCCESS: 200,"New Question with ID 235 has been created (Test ID 38). New Answer with ID 777 has been created (Test ID 38, Question ID 235).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify steps for engaging patients in successful management of their COPD.</ol>",Agree,False,0,SUCCESS: 200,"New Answer with ID 778 has been created (Test ID 38, Question ID 235).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify steps for engaging patients in successful management of their COPD.</ol>",No Opinion,False,0,SUCCESS: 200,"New Answer with ID 779 has been created (Test ID 38, Question ID 235).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify steps for engaging patients in successful management of their COPD.</ol>",Disagree,False,0,SUCCESS: 200,"New Answer with ID 780 has been created (Test ID 38, Question ID 235).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify steps for engaging patients in successful management of their COPD.</ol>",Strongly Disagree,False,0,SUCCESS: 200,"New Answer with ID 781 has been created (Test ID 38, Question ID 235).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify COPD ΓÇ£masqueradersΓÇ¥ and/or co-existent conditions to monitor. </ol>",Strongly Agree,False,0,SUCCESS: 200,"New Question with ID 236 has been created (Test ID 38). New Answer with ID 782 has been created (Test ID 38, Question ID 236).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify COPD ΓÇ£masqueradersΓÇ¥ and/or co-existent conditions to monitor. </ol>",Agree,False,0,SUCCESS: 200,"New Answer with ID 783 has been created (Test ID 38, Question ID 236).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify COPD ΓÇ£masqueradersΓÇ¥ and/or co-existent conditions to monitor. </ol>",No Opinion,False,0,SUCCESS: 200,"New Answer with ID 784 has been created (Test ID 38, Question ID 236).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify COPD ΓÇ£masqueradersΓÇ¥ and/or co-existent conditions to monitor. </ol>",Disagree,False,0,SUCCESS: 200,"New Answer with ID 785 has been created (Test ID 38, Question ID 236).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify COPD ΓÇ£masqueradersΓÇ¥ and/or co-existent conditions to monitor. </ol>",Strongly Disagree,False,0,SUCCESS: 200,"New Answer with ID 786 has been created (Test ID 38, Question ID 236).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss prognostication and symptom management for end-stage COPD.</ol>",Strongly Agree,False,0,SUCCESS: 200,"New Question with ID 237 has been created (Test ID 38). New Answer with ID 787 has been created (Test ID 38, Question ID 237).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss prognostication and symptom management for end-stage COPD.</ol>",Agree,False,0,SUCCESS: 200,"New Answer with ID 788 has been created (Test ID 38, Question ID 237).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss prognostication and symptom management for end-stage COPD.</ol>",No Opinion,False,0,SUCCESS: 200,"New Answer with ID 789 has been created (Test ID 38, Question ID 237).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss prognostication and symptom management for end-stage COPD.</ol>",Disagree,False,0,SUCCESS: 200,"New Answer with ID 790 has been created (Test ID 38, Question ID 237).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss prognostication and symptom management for end-stage COPD.</ol>",Strongly Disagree,False,0,SUCCESS: 200,"New Answer with ID 791 has been created (Test ID 38, Question ID 237).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss goals of care with patients and families impacted by COPD.</ol>",Strongly Agree,False,0,SUCCESS: 200,"New Question with ID 238 has been created (Test ID 38). New Answer with ID 792 has been created (Test ID 38, Question ID 238).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss goals of care with patients and families impacted by COPD.</ol>",Agree,False,0,SUCCESS: 200,"New Answer with ID 793 has been created (Test ID 38, Question ID 238).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss goals of care with patients and families impacted by COPD.</ol>",No Opinion,False,0,SUCCESS: 200,"New Answer with ID 794 has been created (Test ID 38, Question ID 238).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss goals of care with patients and families impacted by COPD.</ol>",Disagree,False,0,SUCCESS: 200,"New Answer with ID 795 has been created (Test ID 38, Question ID 238).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss goals of care with patients and families impacted by COPD.</ol>",Strongly Disagree,False,0,SUCCESS: 200,"New Answer with ID 796 has been created (Test ID 38, Question ID 238).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,Strongly Agree,False,0,SUCCESS: 200,"New Question with ID 239 has been created (Test ID 38). New Answer with ID 797 has been created (Test ID 38, Question ID 239).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,Agree,False,0,SUCCESS: 200,"New Answer with ID 798 has been created (Test ID 38, Question ID 239).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,No Opinion,False,0,SUCCESS: 200,"New Answer with ID 799 has been created (Test ID 38, Question ID 239).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,Disagree,False,0,SUCCESS: 200,"New Answer with ID 800 has been created (Test ID 38, Question ID 239).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,Strongly Disagree,False,0,SUCCESS: 200,"New Answer with ID 801 has been created (Test ID 38, Question ID 239).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",Strongly Agree,False,0,SUCCESS: 200,"New Question with ID 240 has been created (Test ID 38). New Answer with ID 802 has been created (Test ID 38, Question ID 240).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",Agree,False,0,SUCCESS: 200,"New Answer with ID 803 has been created (Test ID 38, Question ID 240).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",No Opinion,False,0,SUCCESS: 200,"New Answer with ID 804 has been created (Test ID 38, Question ID 240).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",Disagree,False,0,SUCCESS: 200,"New Answer with ID 805 has been created (Test ID 38, Question ID 240).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",Strongly Disagree,False,0,SUCCESS: 200,"New Answer with ID 806 has been created (Test ID 38, Question ID 240).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge and confidence in caring for and coaching patients with COPD. </OL>,Strongly Agree,False,0,SUCCESS: 200,"New Question with ID 241 has been created (Test ID 38). New Answer with ID 807 has been created (Test ID 38, Question ID 241).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge and confidence in caring for and coaching patients with COPD. </OL>,Agree,False,0,SUCCESS: 200,"New Answer with ID 808 has been created (Test ID 38, Question ID 241).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge and confidence in caring for and coaching patients with COPD. </OL>,No Opinion,False,0,SUCCESS: 200,"New Answer with ID 809 has been created (Test ID 38, Question ID 241).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge and confidence in caring for and coaching patients with COPD. </OL>,Disagree,False,0,SUCCESS: 200,"New Answer with ID 810 has been created (Test ID 38, Question ID 241).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge and confidence in caring for and coaching patients with COPD. </OL>,Strongly Disagree,False,0,SUCCESS: 200,"New Answer with ID 811 has been created (Test ID 38, Question ID 241).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",Strongly Agree,False,0,SUCCESS: 200,"New Question with ID 242 has been created (Test ID 38). New Answer with ID 812 has been created (Test ID 38, Question ID 242).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",Agree,False,0,SUCCESS: 200,"New Answer with ID 813 has been created (Test ID 38, Question ID 242).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",No Opinion,False,0,SUCCESS: 200,"New Answer with ID 814 has been created (Test ID 38, Question ID 242).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",Disagree,False,0,SUCCESS: 200,"New Answer with ID 815 has been created (Test ID 38, Question ID 242).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",Strongly Disagree,False,0,SUCCESS: 200,"New Answer with ID 816 has been created (Test ID 38, Question ID 242).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.</OL>,Strongly Agree,False,0,SUCCESS: 200,"New Question with ID 243 has been created (Test ID 38). New Answer with ID 817 has been created (Test ID 38, Question ID 243).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.</OL>,Agree,False,0,SUCCESS: 200,"New Answer with ID 818 has been created (Test ID 38, Question ID 243).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.</OL>,No Opinion,False,0,SUCCESS: 200,"New Answer with ID 819 has been created (Test ID 38, Question ID 243).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.</OL>,Disagree,False,0,SUCCESS: 200,"New Answer with ID 820 has been created (Test ID 38, Question ID 243).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.</OL>,Strongly Disagree,False,0,SUCCESS: 200,"New Answer with ID 821 has been created (Test ID 38, Question ID 243).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,Strongly Agree,False,0,SUCCESS: 200,"New Question with ID 244 has been created (Test ID 38). New Answer with ID 822 has been created (Test ID 38, Question ID 244).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,Agree,False,0,SUCCESS: 200,"New Answer with ID 823 has been created (Test ID 38, Question ID 244).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,No Opinion,False,0,SUCCESS: 200,"New Answer with ID 824 has been created (Test ID 38, Question ID 244).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,Disagree,False,0,SUCCESS: 200,"New Answer with ID 825 has been created (Test ID 38, Question ID 244).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,Strongly Disagree,False,0,SUCCESS: 200,"New Answer with ID 826 has been created (Test ID 38, Question ID 244).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Brad Drummond, MD</ol>",Excellent,False,0,SUCCESS: 200,"New Question with ID 245 has been created (Test ID 38). New Answer with ID 827 has been created (Test ID 38, Question ID 245).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Brad Drummond, MD</ol>",Very Good,False,0,SUCCESS: 200,"New Answer with ID 828 has been created (Test ID 38, Question ID 245).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Brad Drummond, MD</ol>",Good,False,0,SUCCESS: 200,"New Answer with ID 829 has been created (Test ID 38, Question ID 245).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Brad Drummond, MD</ol>",Fair,False,0,SUCCESS: 200,"New Answer with ID 830 has been created (Test ID 38, Question ID 245).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Brad Drummond, MD</ol>",Poor,False,0,SUCCESS: 200,"New Answer with ID 831 has been created (Test ID 38, Question ID 245).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Matthew Haack, MD</ol>",Excellent,False,0,SUCCESS: 200,"New Question with ID 246 has been created (Test ID 38). New Answer with ID 832 has been created (Test ID 38, Question ID 246).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Matthew Haack, MD</ol>",Very Good,False,0,SUCCESS: 200,"New Answer with ID 833 has been created (Test ID 38, Question ID 246).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Matthew Haack, MD</ol>",Good,False,0,SUCCESS: 200,"New Answer with ID 834 has been created (Test ID 38, Question ID 246).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Matthew Haack, MD</ol>",Fair,False,0,SUCCESS: 200,"New Answer with ID 835 has been created (Test ID 38, Question ID 246).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Matthew Haack, MD</ol>",Poor,False,0,SUCCESS: 200,"New Answer with ID 836 has been created (Test ID 38, Question ID 246).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Sunil Vallurupalli, MD</ol>",Excellent,False,0,SUCCESS: 200,"New Question with ID 247 has been created (Test ID 38). New Answer with ID 837 has been created (Test ID 38, Question ID 247).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Sunil Vallurupalli, MD</ol>",Very Good,False,0,SUCCESS: 200,"New Answer with ID 838 has been created (Test ID 38, Question ID 247).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Sunil Vallurupalli, MD</ol>",Good,False,0,SUCCESS: 200,"New Answer with ID 839 has been created (Test ID 38, Question ID 247).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Sunil Vallurupalli, MD</ol>",Fair,False,0,SUCCESS: 200,"New Answer with ID 840 has been created (Test ID 38, Question ID 247).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Sunil Vallurupalli, MD</ol>",Poor,False,0,SUCCESS: 200,"New Answer with ID 841 has been created (Test ID 38, Question ID 247).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alanna Breckinridge, PharmD</ol>",Excellent,False,0,SUCCESS: 200,"New Question with ID 248 has been created (Test ID 38). New Answer with ID 842 has been created (Test ID 38, Question ID 248).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alanna Breckinridge, PharmD</ol>",Very Good,False,0,SUCCESS: 200,"New Answer with ID 843 has been created (Test ID 38, Question ID 248).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alanna Breckinridge, PharmD</ol>",Good,False,0,SUCCESS: 200,"New Answer with ID 844 has been created (Test ID 38, Question ID 248).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alanna Breckinridge, PharmD</ol>",Fair,False,0,SUCCESS: 200,"New Answer with ID 845 has been created (Test ID 38, Question ID 248).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alanna Breckinridge, PharmD</ol>",Poor,False,0,SUCCESS: 200,"New Answer with ID 846 has been created (Test ID 38, Question ID 248).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Justin Henao, MD</ol>",Excellent,False,0,SUCCESS: 200,"New Question with ID 249 has been created (Test ID 38). New Answer with ID 847 has been created (Test ID 38, Question ID 249).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Justin Henao, MD</ol>",Very Good,False,0,SUCCESS: 200,"New Answer with ID 848 has been created (Test ID 38, Question ID 249).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Justin Henao, MD</ol>",Good,False,0,SUCCESS: 200,"New Answer with ID 849 has been created (Test ID 38, Question ID 249).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Justin Henao, MD</ol>",Fair,False,0,SUCCESS: 200,"New Answer with ID 850 has been created (Test ID 38, Question ID 249).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Justin Henao, MD</ol>",Poor,False,0,SUCCESS: 200,"New Answer with ID 851 has been created (Test ID 38, Question ID 249).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Haider Ali, MD</ol>",Excellent,False,0,SUCCESS: 200,"New Question with ID 250 has been created (Test ID 38). New Answer with ID 852 has been created (Test ID 38, Question ID 250).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Haider Ali, MD</ol>",Very Good,False,0,SUCCESS: 200,"New Answer with ID 853 has been created (Test ID 38, Question ID 250).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Haider Ali, MD</ol>",Good,False,0,SUCCESS: 200,"New Answer with ID 854 has been created (Test ID 38, Question ID 250).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Haider Ali, MD</ol>",Fair,False,0,SUCCESS: 200,"New Answer with ID 855 has been created (Test ID 38, Question ID 250).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Haider Ali, MD</ol>",Poor,False,0,SUCCESS: 200,"New Answer with ID 856 has been created (Test ID 38, Question ID 250).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Gregory Mauldin, MD</ol>",Excellent,False,0,SUCCESS: 200,"New Question with ID 251 has been created (Test ID 38). New Answer with ID 857 has been created (Test ID 38, Question ID 251).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Gregory Mauldin, MD</ol>",Very Good,False,0,SUCCESS: 200,"New Answer with ID 858 has been created (Test ID 38, Question ID 251).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Gregory Mauldin, MD</ol>",Good,False,0,SUCCESS: 200,"New Answer with ID 859 has been created (Test ID 38, Question ID 251).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Gregory Mauldin, MD</ol>",Fair,False,0,SUCCESS: 200,"New Answer with ID 860 has been created (Test ID 38, Question ID 251).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Gregory Mauldin, MD</ol>",Poor,False,0,SUCCESS: 200,"New Answer with ID 861 has been created (Test ID 38, Question ID 251).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Paul Weinberg, MD</ol>",Excellent,False,0,SUCCESS: 200,"New Question with ID 252 has been created (Test ID 38). New Answer with ID 862 has been created (Test ID 38, Question ID 252).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Paul Weinberg, MD</ol>",Very Good,False,0,SUCCESS: 200,"New Answer with ID 863 has been created (Test ID 38, Question ID 252).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Paul Weinberg, MD</ol>",Good,False,0,SUCCESS: 200,"New Answer with ID 864 has been created (Test ID 38, Question ID 252).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Paul Weinberg, MD</ol>",Fair,False,0,SUCCESS: 200,"New Answer with ID 865 has been created (Test ID 38, Question ID 252).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Paul Weinberg, MD</ol>",Poor,False,0,SUCCESS: 200,"New Answer with ID 866 has been created (Test ID 38, Question ID 252).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Raxit Patel, MD</ol>",Excellent,False,0,SUCCESS: 200,"New Question with ID 253 has been created (Test ID 38). New Answer with ID 867 has been created (Test ID 38, Question ID 253).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Raxit Patel, MD</ol>",Very Good,False,0,SUCCESS: 200,"New Answer with ID 868 has been created (Test ID 38, Question ID 253).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Raxit Patel, MD</ol>",Good,False,0,SUCCESS: 200,"New Answer with ID 869 has been created (Test ID 38, Question ID 253).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Raxit Patel, MD</ol>",Fair,False,0,SUCCESS: 200,"New Answer with ID 870 has been created (Test ID 38, Question ID 253).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Raxit Patel, MD</ol>",Poor,False,0,SUCCESS: 200,"New Answer with ID 871 has been created (Test ID 38, Question ID 253).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rani Kumaran, MD</ol>",Excellent,False,0,SUCCESS: 200,"New Question with ID 254 has been created (Test ID 38). New Answer with ID 872 has been created (Test ID 38, Question ID 254).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rani Kumaran, MD</ol>",Very Good,False,0,SUCCESS: 200,"New Answer with ID 873 has been created (Test ID 38, Question ID 254).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rani Kumaran, MD</ol>",Good,False,0,SUCCESS: 200,"New Answer with ID 874 has been created (Test ID 38, Question ID 254).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rani Kumaran, MD</ol>",Fair,False,0,SUCCESS: 200,"New Answer with ID 875 has been created (Test ID 38, Question ID 254).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rani Kumaran, MD</ol>",Poor,False,0,SUCCESS: 200,"New Answer with ID 876 has been created (Test ID 38, Question ID 254).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Simha Jagadeesh, MD</ol>",Excellent,False,0,SUCCESS: 200,"New Question with ID 255 has been created (Test ID 38). New Answer with ID 877 has been created (Test ID 38, Question ID 255).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Simha Jagadeesh, MD</ol>",Very Good,False,0,SUCCESS: 200,"New Answer with ID 878 has been created (Test ID 38, Question ID 255).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Simha Jagadeesh, MD</ol>",Good,False,0,SUCCESS: 200,"New Answer with ID 879 has been created (Test ID 38, Question ID 255).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Simha Jagadeesh, MD</ol>",Fair,False,0,SUCCESS: 200,"New Answer with ID 880 has been created (Test ID 38, Question ID 255).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Simha Jagadeesh, MD</ol>",Poor,False,0,SUCCESS: 200,"New Answer with ID 881 has been created (Test ID 38, Question ID 255).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Huda Sayeed, MD</ol>",Excellent,False,0,SUCCESS: 200,"New Question with ID 256 has been created (Test ID 38). New Answer with ID 882 has been created (Test ID 38, Question ID 256).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Huda Sayeed, MD</ol>",Very Good,False,0,SUCCESS: 200,"New Answer with ID 883 has been created (Test ID 38, Question ID 256).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Huda Sayeed, MD</ol>",Good,False,0,SUCCESS: 200,"New Answer with ID 884 has been created (Test ID 38, Question ID 256).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Huda Sayeed, MD</ol>",Fair,False,0,SUCCESS: 200,"New Answer with ID 885 has been created (Test ID 38, Question ID 256).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Huda Sayeed, MD</ol>",Poor,False,0,SUCCESS: 200,"New Answer with ID 886 has been created (Test ID 38, Question ID 256).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Jill Rossrucker, MD</ol>",Excellent,False,0,SUCCESS: 200,"New Question with ID 257 has been created (Test ID 38). New Answer with ID 887 has been created (Test ID 38, Question ID 257).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Jill Rossrucker, MD</ol>",Very Good,False,0,SUCCESS: 200,"New Answer with ID 888 has been created (Test ID 38, Question ID 257).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Jill Rossrucker, MD</ol>",Good,False,0,SUCCESS: 200,"New Answer with ID 889 has been created (Test ID 38, Question ID 257).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Jill Rossrucker, MD</ol>",Fair,False,0,SUCCESS: 200,"New Answer with ID 890 has been created (Test ID 38, Question ID 257).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Jill Rossrucker, MD</ol>",Poor,False,0,SUCCESS: 200,"New Answer with ID 891 has been created (Test ID 38, Question ID 257).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Steven Accarino, MD</ol>",Excellent,False,0,SUCCESS: 200,"New Question with ID 258 has been created (Test ID 38). New Answer with ID 892 has been created (Test ID 38, Question ID 258).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Steven Accarino, MD</ol>",Very Good,False,0,SUCCESS: 200,"New Answer with ID 893 has been created (Test ID 38, Question ID 258).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Steven Accarino, MD</ol>",Good,False,0,SUCCESS: 200,"New Answer with ID 894 has been created (Test ID 38, Question ID 258).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Steven Accarino, MD</ol>",Fair,False,0,SUCCESS: 200,"New Answer with ID 895 has been created (Test ID 38, Question ID 258).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Steven Accarino, MD</ol>",Poor,False,0,SUCCESS: 200,"New Answer with ID 896 has been created (Test ID 38, Question ID 258).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"Overall, this activity was:",Excellent,False,0,SUCCESS: 200,"New Question with ID 259 has been created (Test ID 38). New Answer with ID 897 has been created (Test ID 38, Question ID 259).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"Overall, this activity was:",Very Good,False,0,SUCCESS: 200,"New Answer with ID 898 has been created (Test ID 38, Question ID 259).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"Overall, this activity was:",Good,False,0,SUCCESS: 200,"New Answer with ID 899 has been created (Test ID 38, Question ID 259).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"Overall, this activity was:",Fair,False,0,SUCCESS: 200,"New Answer with ID 900 has been created (Test ID 38, Question ID 259).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"Overall, this activity was:",Poor,False,0,SUCCESS: 200,"New Answer with ID 901 has been created (Test ID 38, Question ID 259).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",Yes,False,0,SUCCESS: 200,"New Question with ID 260 has been created (Test ID 38). New Answer with ID 902 has been created (Test ID 38, Question ID 260).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",No,False,0,SUCCESS: 200,"New Answer with ID 903 has been created (Test ID 38, Question ID 260).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",N/A,False,0,SUCCESS: 200,"New Answer with ID 904 has been created (Test ID 38, Question ID 260).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,How would you improve this class?,Reduce content covered in class,False,0,SUCCESS: 200,"New Question with ID 261 has been created (Test ID 38). New Answer with ID 905 has been created (Test ID 38, Question ID 261).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,How would you improve this class?,Increase content covered in class,False,0,SUCCESS: 200,"New Answer with ID 906 has been created (Test ID 38, Question ID 261).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,How would you improve this class?,Update content covered in class,False,0,SUCCESS: 200,"New Answer with ID 907 has been created (Test ID 38, Question ID 261).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,How would you improve this class?,Improve the instructional methods,False,0,SUCCESS: 200,"New Answer with ID 908 has been created (Test ID 38, Question ID 261).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,How would you improve this class?,Make course activities more stimulating,False,0,SUCCESS: 200,"New Answer with ID 909 has been created (Test ID 38, Question ID 261).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,How would you improve this class?,Slow the pace of the class,False,0,SUCCESS: 200,"New Answer with ID 910 has been created (Test ID 38, Question ID 261).",True
1196,ILT-0000-4819,ILT-0000-4819,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20,g9867,COPD SYMPOSIUM: STATE OF THE ART CARE (EVALUATION SURVEY)  ALPHARETTA  3.7.20- g9867,choice,How would you improve this class?,"Nothing: (appropriate speakers, content, facility, etc.)",False,0,SUCCESS: 200,"New Answer with ID 911 has been created (Test ID 38, Question ID 261).",True
